Overview Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 Extended Release (ER) Status: Active, not recruiting Trial end date: 2024-06-01 Target enrollment: Participant gender: Summary Open label, flexible dose, long-term multicenter study of safety and efficacy of SPN-812 ER in pediatric ADHD patients Phase: Phase 3 Details Lead Sponsor: Supernus Pharmaceuticals, Inc.